To determine the efficacy and safety of CP obtained from whole blood in patients with COVID-19.
Pilot clinical trial in patients with COVID-19 from a general hospital. The subjects were separated into three groups that received the transfusion of 400ml of CP (n=23) or 400ml of standard plasma (SP) (n=19) and a non-transfused group (NT) (n=37). Patients also received the standard available medical treatment for COVID-19. Subjects were followed up daily from admission to day 21.
The CP did not improve the survival curve in moderate and severe variants of COVID-19, nor did it reduce the degree of severity of the disease evaluated with the COVID-19 WHO and SOFA clinical progression scale. No patient had a severe post-transfusion reaction to CP.
Treatment with CP does not reduce the mortality of patients even when its administration has a high degree of safety.
目的:确定全血CP对COVID-19患者的疗效和安全性。
方法:在综合医院的COVID-19患者中进行试点临床试验。将受试者分为接受400mlCP(n=23)或400ml标准血浆(SP)(n=19)和未输注组(NT)(n=37)的三组。患者还接受了COVID-19的标准药物治疗。从入院到第21天,每天对受试者进行随访。
结果:CP没有改善COVID-19中度和重度变体的存活曲线,也没有降低COVID-19和SOFA临床进展量表评估的疾病严重程度。没有患者对CP有严重的输血后反应。
结论:CP治疗并不能降低患者的死亡率,即使其给药具有高度的安全性。